Evidence map›Paper›PMID 23065385›Full record

ArticleCirculation2012

Ribosomal protein L17, RpL17, is an inhibitor of vascular smooth muscle growth and carotid intima formation.

Elaine M Smolock, Vyacheslav A Korshunov, Galina Glazko, Xing Qiu, Janice Gerloff, Bradford C Berk

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Circulation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 70 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. KArtery research · 2021
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Mechanical Regulation of Protein Translation in the Cardiovascular System.Frontiers in cell and developmental biology · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Elaine M SmolockAab Cardiovascular Research Institute, University of Rochester School of Medicine & Dentistry, Rochester, NY 14642, USA. Elaine_Smolock@URMC.rochester.edu
Vyacheslav A Korshunov
Galina Glazko
Xing Qiu
Janice Gerloff
Bradford C Berk
University of Rochester · US

Funding

GENETICS OF VASCULAR REMODELING IN HYPERTENSIONR01HL062826 · NHLBI · UNIVERSITY OF ROCHESTER · PI BERK, BRADFORD C · 1999 to 2013
$4.2M
Role of Ribosomal Proteins in Vascular Smooth Muscle Cell ProliferationF32HL093986 · NHLBI · UNIVERSITY OF ROCHESTER · PI SMOLOCK, ELAINE M · 2009 to 2010
$102k
NHLBI NIH HHS F32 HL093986NHLBI NIH HHS HL093986NHLBI NIH HHS HL-62826NHLBI NIH HHS R01 HL062826
6 · The paper itself

Abstract

backgroundCarotid intima-media thickening is associated with increased cardiovascular risk in humans. We discovered that intima formation and cell proliferation in response to carotid injury is greater in SJL/J (SJL) in comparison with C3HeB/FeJ (C3H/F) mice. The purpose of this study was to identify candidate genes contributing to intima formation. METHODS AND

resultsWe performed microarray and bioinformatic analyses of carotid arteries from C3H/F and SJL mice. Kyoto Encyclopedia of Genes and Genomes analysis showed that the ribosome pathway was significantly up-regulated in C3H/F in comparison with SJL mice. Expression of a ribosomal protein, RpL17, was >40-fold higher in C3H/F carotids in comparison with SJL. Aortic vascular smooth muscle cells from C3H/F grew slower in comparison to SJL. To determine the role of RpL17 in vascular smooth muscle cell growth regulation, we analyzed the relationship between RpL17 expression and cell cycle progression. Cultured vascular smooth muscle cells from mice, rats, and humans showed that RpL17 expression inversely correlated with growth as shown by decreased cells in S phase and increased cells in G(0)/G(1). To prove that RpL17 acted as a growth inhibitor in vivo, we used pluronic gel delivery of RpL17 small interfering RNA to C3H/F carotid arteries. This resulted in an 8-fold increase in the number of proliferating cells. Furthermore, following partial carotid ligation in SJL mice, RpL17 expression in the intima and media decreased, but the number of proliferating cells increased.

conclusionsRpL17 acts as a vascular smooth muscle cell growth inhibitor (akin to a tumor suppressor) and represents a potential therapeutic target to limit carotid intima-media thickening.

Indexed as

Cell ProliferationAnimalsCarotid ArteriesCell CycleCells, CulturedComputational BiologyG1 PhaseHumansMaleMiceMice, Inbred C3HMice, Inbred StrainsMicroarray AnalysisMuscle, Smooth, VascularRatsResting Phase, Cell Cycleribosomal protein L17Ribosomal Proteins

Identifiers

PMID23065385
PMCPMC3502943
OpenAlexW2095318074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.